NO20061791L - Polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline - Google Patents
Polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinolineInfo
- Publication number
- NO20061791L NO20061791L NO20061791A NO20061791A NO20061791L NO 20061791 L NO20061791 L NO 20061791L NO 20061791 A NO20061791 A NO 20061791A NO 20061791 A NO20061791 A NO 20061791A NO 20061791 L NO20061791 L NO 20061791L
- Authority
- NO
- Norway
- Prior art keywords
- phenylsulfonyl
- piperazin
- quinoline
- polymorphic form
- cns
- Prior art date
Links
- JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Det er beskrevet en ny forbindelse, 3-fenylsulfonyl-8-piperazin-l-yl-kinolin, fremgangsmåte for fremstilling derav, preparater inneholdende denne og dens anvendelse ved behandling av CNS og andre lidelser.There is disclosed a novel compound, 3-phenylsulfonyl-8-piperazin-1-yl-quinoline, process for its preparation, compositions containing it and its use in the treatment of CNS and other disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0322629.7A GB0322629D0 (en) | 2003-09-26 | 2003-09-26 | Novel compound |
| PCT/EP2004/010843 WO2005040124A1 (en) | 2003-09-26 | 2004-09-23 | A polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061791L true NO20061791L (en) | 2006-04-24 |
Family
ID=29286934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061791A NO20061791L (en) | 2003-09-26 | 2006-04-24 | Polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070032504A1 (en) |
| EP (1) | EP1667975B1 (en) |
| JP (1) | JP2007506702A (en) |
| CN (1) | CN1856471A (en) |
| AU (1) | AU2004283805A1 (en) |
| BR (1) | BRPI0414678A (en) |
| CA (1) | CA2540022A1 (en) |
| CO (1) | CO5680402A2 (en) |
| DE (1) | DE602004010410T2 (en) |
| DK (1) | DK1667975T3 (en) |
| ES (1) | ES2297465T3 (en) |
| GB (1) | GB0322629D0 (en) |
| HR (1) | HRP20080055T3 (en) |
| IL (1) | IL174213A0 (en) |
| IS (1) | IS8399A (en) |
| MA (1) | MA28093A1 (en) |
| MX (1) | MXPA06003375A (en) |
| NO (1) | NO20061791L (en) |
| PL (1) | PL1667975T3 (en) |
| PT (1) | PT1667975E (en) |
| RU (1) | RU2355681C2 (en) |
| WO (1) | WO2005040124A1 (en) |
| ZA (1) | ZA200601453B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2309154C9 (en) * | 2002-03-27 | 2016-09-27 | Глэксо Груп Лимитед | 3-phenylsulfonyl-8-piperazin-1-yl-quinolines having affinity to 5-ht6receptor, methods for production thereof (variants) |
| DE602004000260T2 (en) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | DIARYL AND ARYLHETEROARYL DRUG DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR SUITABLE FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES THEREOF |
| PT1663958E (en) | 2003-09-18 | 2015-06-01 | Virobay Inc | Haloalkyl containing compounds as cysteine protease inhibitors |
| MX2007014929A (en) | 2005-06-02 | 2008-02-15 | Hoffmann La Roche | 3-methanesulfonylquinolines as gaba-b enhancers. |
| GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
| US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| BR112018000728A2 (en) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | method for the prophylaxis and / or treatment of visual hallucinations in a subject in need |
| WO2017202206A1 (en) * | 2016-05-27 | 2017-11-30 | 深圳市塔吉瑞生物医药有限公司 | Substituted quinoline compound and pharmaceutical composition thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| RU2309154C9 (en) * | 2002-03-27 | 2016-09-27 | Глэксо Груп Лимитед | 3-phenylsulfonyl-8-piperazin-1-yl-quinolines having affinity to 5-ht6receptor, methods for production thereof (variants) |
| GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
-
2003
- 2003-09-26 GB GBGB0322629.7A patent/GB0322629D0/en not_active Ceased
- 2003-09-26 PT PT04765655T patent/PT1667975E/en unknown
-
2004
- 2004-09-23 EP EP04765655A patent/EP1667975B1/en not_active Expired - Lifetime
- 2004-09-23 PL PL04765655T patent/PL1667975T3/en unknown
- 2004-09-23 AU AU2004283805A patent/AU2004283805A1/en not_active Abandoned
- 2004-09-23 CA CA002540022A patent/CA2540022A1/en not_active Abandoned
- 2004-09-23 RU RU2006114024/04A patent/RU2355681C2/en active
- 2004-09-23 JP JP2006527373A patent/JP2007506702A/en not_active Withdrawn
- 2004-09-23 US US10/572,670 patent/US20070032504A1/en not_active Abandoned
- 2004-09-23 ES ES04765655T patent/ES2297465T3/en not_active Expired - Lifetime
- 2004-09-23 HR HR20080055T patent/HRP20080055T3/en unknown
- 2004-09-23 DE DE602004010410T patent/DE602004010410T2/en not_active Expired - Fee Related
- 2004-09-23 CN CNA2004800275278A patent/CN1856471A/en active Pending
- 2004-09-23 MX MXPA06003375A patent/MXPA06003375A/en active IP Right Grant
- 2004-09-23 BR BRPI0414678-6A patent/BRPI0414678A/en not_active IP Right Cessation
- 2004-09-23 DK DK04765655T patent/DK1667975T3/en active
- 2004-09-23 WO PCT/EP2004/010843 patent/WO2005040124A1/en not_active Ceased
-
2006
- 2006-02-20 ZA ZA200601453A patent/ZA200601453B/en unknown
- 2006-03-09 IL IL174213A patent/IL174213A0/en unknown
- 2006-03-27 CO CO06030123A patent/CO5680402A2/en not_active Application Discontinuation
- 2006-04-05 IS IS8399A patent/IS8399A/en unknown
- 2006-04-13 MA MA28933A patent/MA28093A1/en unknown
- 2006-04-24 NO NO20061791A patent/NO20061791L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1856471A (en) | 2006-11-01 |
| GB0322629D0 (en) | 2003-10-29 |
| HK1094190A1 (en) | 2007-03-23 |
| CA2540022A1 (en) | 2005-05-06 |
| PL1667975T3 (en) | 2008-04-30 |
| HRP20080055T3 (en) | 2008-02-29 |
| CO5680402A2 (en) | 2006-09-29 |
| RU2006114024A (en) | 2007-11-10 |
| AU2004283805A1 (en) | 2005-05-06 |
| IS8399A (en) | 2006-04-05 |
| EP1667975B1 (en) | 2007-11-28 |
| US20070032504A1 (en) | 2007-02-08 |
| ES2297465T3 (en) | 2008-05-01 |
| MXPA06003375A (en) | 2006-06-08 |
| IL174213A0 (en) | 2006-08-01 |
| DK1667975T3 (en) | 2008-04-14 |
| EP1667975A1 (en) | 2006-06-14 |
| BRPI0414678A (en) | 2006-11-28 |
| WO2005040124A1 (en) | 2005-05-06 |
| DE602004010410T2 (en) | 2008-10-16 |
| PT1667975E (en) | 2008-02-29 |
| ZA200601453B (en) | 2007-04-25 |
| MA28093A1 (en) | 2006-08-01 |
| DE602004010410D1 (en) | 2008-01-10 |
| RU2355681C2 (en) | 2009-05-20 |
| JP2007506702A (en) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03011484A (en) | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease. | |
| DK1648905T3 (en) | Inhibitors of thienopyridine and furopyridine kinase | |
| EA200501274A1 (en) | PYRAZOLES AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| TW200504015A (en) | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | |
| NO20073140L (en) | Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases | |
| EA200700851A1 (en) | OBTAINING AND APPLICATION OF BIPHENYL-4-ILKARBONYLAMINO ACID DERIVATIVES FOR TREATMENT OF OBESITY | |
| TW200510317A (en) | Caspase inhibitors and uses thereof | |
| WO2006050109A3 (en) | Novel kinase inhibitors | |
| NO20006645D0 (en) | New form of irbesartan, process for obtaining said form and pharmaceutical preparations containing the same | |
| SE0301368D0 (en) | Chemical compounds | |
| NO20061791L (en) | Polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline | |
| MX2010002938A (en) | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1- carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating. | |
| NO20043016L (en) | 6-aminomorphinan derivatives, process for preparation and use thereof | |
| NO20062256L (en) | Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones | |
| MXPA05009151A (en) | Heterocyclic kinase inhibitors. | |
| WO2004043379A3 (en) | Chemical compounds | |
| GB0322510D0 (en) | Novel compounds | |
| SE0300850D0 (en) | Chemical compounds | |
| HRP20080057T3 (en) | 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof | |
| DE60329326D1 (en) | TACE INHIBITORS | |
| ATE359283T1 (en) | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | |
| SE0200844D0 (en) | Chemical compounds | |
| SE0200843D0 (en) | Chemical compounds | |
| ATE419242T1 (en) | PYRROLIDINYLUREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | |
| SE0300957D0 (en) | Chemical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |